Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor | Molecular Pharmacology

Submit a Response to This Article

Compose eLetter

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

No

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

In this issue

Related Articles

Cited By...

More in this TOC Section

Coordinated Transcriptional Regulation of Cytochrome P450 3As by Nuclear Transcription Factor Y (NF-Y) and Specificity Protein 1 (Sp1)
Protocol-dependent differences in IC50 values measured in hERG assays occur in a predictable way and can be used to quantify state preference of drug binding.
Statins perturb Gβγ signaling and cell behaviors in a Gγ subtype dependent manner

Show more Articles

Similar Articles